Download Type 2 Diabetes: Investigational empagliflozin

MEDIA RELEASE
For more information
Newsroom
Businesswire Australia and New Zealand
[email protected]
17-Sep-2014 7:32 AM
Topic: Health
Type 2 Diabetes: Investigational
empagliflozin/linagliptin combination tablet shows
sustained reduction in blood glucose in Phase III
study
INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--Boehringer Ingelheim and Eli Lilly and Company
today presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational
empagliflozin/linagliptin combination tablet in adults with type 2 diabetes (T2D) already taking metformin and in
those who were previously untreated. Results from the study, presented during the 50th Annual Meeting of the
European Association for the Study of Diabetes (EASD), also confirmed the safety profile of the combination tablet.
“We are encouraged by the results of this study because it showed clinically meaningful reductions in blood glucose
levels with the empagliflozin/linagliptin combination when used with or without metformin”
“We are encouraged by the results of this study because it showed clinically meaningful reductions in blood glucose
levels with the empagliflozin/linagliptin combination when used with or without metformin,” said Prof Hans-J. Woerle,
Vice President, Head of medicine, Therapeutic Area Metabolism, Boehringer Ingelheim. “As Type 2 Diabetes is a
complex and progressive condition, new treatment approaches may be required to help control blood glucose and
the single tablet combination of empagliflozin/linagliptin may provide an important option for these patients.”
About the study
In the parallel group study, 1,363 adults with T2D were randomised to five groups to investigate the efficacy and
safety of two doses of the empagliflozin/linagliptin combination tablet compared to two doses of empagliflozin and
one dose of linagliptin with or without metformin. Overall, empagliflozin/linagliptin combination therapy was well
tolerated, with safety profiles similar to those known for the individual components. Patients were randomised to one
the following treatments:





Empagliflozin 25mg/linagliptin 5mg, combination tablet
Empagliflozin 10mg/linagliptin 5mg, combination tablet
Empagliflozin 25mg
Empagliflozin 10mg
Linagliptin 5mg
Empagliflozin/linagliptin combination therapy as add-on to stable dose metformin



At 52 weeks, both empagliflozin 25mg/linagliptin 5mg and empagliflozin 10mg/linagliptin 5mg led to
significant reductions in blood glucose (HbA1c) of -1.21 and -1.04 percent, respectively, compared to
baseline. The glucose lowering effects of the other treatments were as follows: linagliptin 5mg (-0.45
percent), empagliflozin 25mg (-0.69 percent) and empagliflozin 10mg (-0.70 percent).
Confirmed hypoglycaemic adverse events (AEs) were reported in 3.6 percent, 2.2 percent, 3.5 percent, 1.4
percent and 2.3 percent of subjects on empagliflozin 25mg/linagliptin 5mg, empagliflozin 10mg/linagliptin
5mg, empagliflozin 25 mg, empagliflozin 10mg and linagliptin 5mg respectively; no subject required
assistance.
Genital infection was reported in 2.2 percent, 5.9 percent, 8.5 percent, 7.9 percent and 2.3 percent, on the
same regimens respectively. Urinary tract infections were reported in 10.2 percent, 9.6 percent, 13.5
percent, 11.4 percent and 15.2 percent, on the same regimens respectively.
Empagliflozin/linagliptin combination therapy in previously untreated adults with T2D



At 52 weeks, both empagliflozin 25mg/linagliptin 5mg and empagliflozin 10mg/linagliptin 5mg led to
reductions in blood glucose (HbA1c) compared to baseline of -1.18 and -1.25 percent, respectively, as did
linagliptin 5mg (-0.51 percent), empagliflozin 25mg (-1.02 percent) and empagliflozin 10mg (-0.87 percent).
The reduction in blood glucose for empagliflozin 10mg/linagliptin 5mg combination tablet was statistically
significant compared with empagliflozin 10mg or linagliptin 5mg; however, reductions seen with
empagliflozin 25mg/linagliptin 5mg did not reach statistical significance compared with empagliflozin 25mg.
Confirmed hypoglycaemic AEs were reported in 1 patient each in both the empagliflozin 25mg and linagliptin

5mg groups and 4 patients on empagliflozin 10mg; no subject required assistance.
Genital infection was reported in 5.9 percent, 2.9 percent, 4.4 percent, 5.2 percent and 3.0 percent in
empagliflozin 25mg/linagliptin 5mg, empagliflozin 10mg/linagliptin 5mg, empagliflozin 25mg, empagliflozin
10mg and linagliptin 5mg. Urinary tract infections were reported in 12.5 percent, 15.4 percent, 10.4 percent,
16.3 percent and 10.4 percent, on the same regimens respectively.
In April this year, Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly announced the U.S. Food and Drug
Administration (FDA) accepted the filing of the New Drug Application for the investigational oral combination of
empagliflozin/linagliptin in a single tablet for the treatment of T2D. If granted approval by the FDA, this combination
will bring together, for the first time into one tablet, the distinct mechanisms of action of a sodium glucose cotransporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor.
Please click on the link below for 'Notes to Editors' and 'References':
http://www.boehringeringelheim.com/news/news_releases/press_releases/2014/16_september_2014_diabetes.html
Contacts
Marco Winkler
Product Communication Manager
Boehringer Ingelheim GmbH
Email: [email protected]
Phone: +49 (151) 689 46812
or
Tammy Hull
Communications Manager
Lilly Diabetes
Email: [email protected]
Phone: +1 (317) 651 9116
About Businesswire
Tens of thousands of communications and organisations around the world trust Business Wire to issue their press
releases, multimedia and regulatory filings to news media, digital platforms, regulatory authorities and industry
influencers. With thousands of distribution and targeting options that reach 162 countries in 50+ languages and 193
industry trade categories, Business Wire gives you access to the world's most powerful press release network. Built
on our patented simultaneous and secure NX network and augmented with partnerships with international and
national news agencies, Business Wire is a valued and trusted source for breaking news by reporters, investors and
consumers. Founded in 1961, Business Wire has 32 bureaus around the globe and is a fully owned subsidiary of
Berkshire Hathaway, a Fortune 5 company.
On Twitter: businesswire
On LinkedIn: http://www.linkedin.com/company/business-wire
More from Business Wire Australia and New Zealand
Get the latest media releases, subscribe to release alerts, and download print and web ready media files at:
http://newsboost.com/newsroom/businesswire